Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial

Motzer, RJ; Escudier, B; George, S; Hammers, HJ; Srinivas, S; Tykodi, SS; Sosman, JA; Plimack, ER; Procopio, G; McDermott, DF; Castellano, D; Choueiri, TK; Donskov, F; Gurney, H; Oudard, S; Richardet, M; Peltola, K; Alva, AS; Carducci, M; Wagstaff, J; Chevreau, C; Fukasawa, S; Tomita, Y; Gauler, TC; Kollmannsberger, CK; Schutz, FA; Larkin, J; Cella, D; McHenry, MB; Saggi, SS; Tannir, NM

Motzer, RJ (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA.

CANCER, 2020; 126 (18): 4156

Abstract

Background CheckMate 025 has shown superior efficacy for nivolumab over everolimus in patients with advanced renal cell carcinoma (aRCC) along with im......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索